medigraphic.com
ISSN 1527-3172 (Digital)

2013, Número 1

<< Anterior Siguiente >>

MEDICC Review 2013; 15 (1)


Heberprot-P: un nuevo producto para el tratamiento de las úlceras complejas del pie diabético

Berlanga J, Fernández JI, López E, López PA, del Río A, Valenzuela C, Baldomero J, Muzio V, Raíces M, Silva R, Acevedo BE, Herrera L

Idioma: Español
Referencias bibliográficas: 49
Paginas: 11-15
Archivo PDF: 295.06 Kb.


RESUMEN

La úlcera del pie diabético es una de las principales complicaciones de la diabetes mellitus. Se ha demostrado que los diabéticos tienen una reducción de las concentraciones de los factores de crecimiento en sus tejidos, en particular del factor de crecimiento epidérmico. Esta reducción perjudica la cicatrización de las heridas, conduce a la cronicidad del trastorno y eventualmente a la amputación. La úlcera del pie diabético isquémico es la más difícil de tratar y tiene el mayor riesgo de amputación.
La inyección del factor de crecimiento epidérmico en los planos profundos y los bordes de la úlcera, estimula una respuesta farmacodinámica más eficaz del crecimiento del tejido de granulación y del cierre de la herida. El factor de crecimiento epidérmico que se inyecta en el nicho de la úlcera también puede asociarse con otras proteínas celulares externas al nicho, aumentando así la proliferación y la migración celular.
El Heberprot-P es un producto cubano novedoso, que contiene factor de crecimiento epidérmico humano recombinante para la infiltración perilesional e intralesional. Las evidencias muestran que acelera la curación de las úlceras profundas y complejas, tanto isquémicas como neuropáticas, y reduce las amputaciones relacionadas con la diabetes.
Los ensayos clínicos del Heberprot-P en pacientes con úlceras del pie diabético han demostrado que la infiltración local repetida de este producto puede mejorar la cicatrización de las heridas crónicas con seguridad y eficacia. Como resultado, el Heberprot-P se registró en Cuba en 2006 y en 2007 fue incluido en el Cuadro Básico de Medicamentos y aprobado para su comercialización. Su registro en otros 21 países ha permitido el tratamiento de más de 150 000 pacientes.
El Heberprot-P es el tratamiento único para las úlceras crónicas más complicadas y rebeldes, por lo general asociadas con el riesgo de amputación. La inyección local en úlceras diabéticas complejas ha demostrado una favorable relación riesgo-beneficio al acelerar la curación, reducir la recurrencia y atenuar el riesgo de amputación. La realización de otros ensayos y la extensión mundial del Heberprot-P brindarían la oportunidad de evaluar las potencialidades del producto para enfrentar una importante necesidad médica no satisfecha.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Davis WA, Norman PE, Bruce DG, Davis TM. Predictors, consequences and cost of diabetesrelated lower extremity amputation complicating type 2 diabetes: the Fremantle Diabetes Study. Diabetologia. 2006 Nov;49(11):2634–41.

  2. Berlanga J, Schultz G, Lopez P. Biology of the diabetic wound. In: Overhaussen PE, editor. Foot ulcers: causes, diagnosis and treatments. New York: Nova Science Publishers, Inc.; 2009.

  3. Schultz G, Berlanga J, Cowan L, Stechmiller J. Linking the advanced glycation endproducts/ receptor for advanced glycation endproduts pathway in diabetics with inflammation and topical antiinflammatory treatments of chronic wound. In: Chandan S, editor. Advances in Wound Care. Columbus (US): Ohio State University Medical Center; 2009. Chapter 44. Vol 1.

  4. CDC Online Press Release [Internet]. Atlanta: Center for Disease Control and Prevention (US); [reviewed 2012 Nov 12; cited 2012 Sep 18]. Disponible en: www.cdc.gov/diabetes/

  5. Li Y, Burrows NR, Gregg EW, Albright A, Geiss LS. Declining rates of hospitalization for nontraumatic lower-extremity amputation in the diabetic population aged 40 years or older: U.S., 1988–2008. Diabetes Care. 2012 Feb;35(2):273–7.

  6. International Working Group on the Diabetic Foot [Internet]. Brussels: International Diabetes Federation; c2000–2005. Foot Note Brazil; [cited 2012 Nov 5]; [about 1 screen]. Disponible en: http://www.iwgdf.org/index.php?Itemid =37&id=10&option=com_content&task=view

  7. Anuario Estadístico de Salud 2010. Havana: Ministry of Public Health (CU); 2011 Apr.

  8. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care. 2008 Mar;31(3):596–615.

  9. Driver VR, Fabbi M, Lavery LA, Gibbons G. The costs of diabetic foot: the economic case for the limb salvage team. J Am Podiatr Med Assoc. 2010 Sep–Oct;100(5):335–41.

  10. Carls GS, Gibson TB, Driver VR, Wrobel JS, Garoufalis MG, Defrancis RR, et al. The economic value of specialized lower-extremity medical care by podiatric physicians in the treatment of diabetic foot ulcers. J Am Podiatr Med Assoc. 2011 Mar–Apr;101(2):93–115.

  11. Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled doubleblind study. Diabetes Care. 1998 May;21(5):822–7.

  12. Armstrong DG, Lipsky BA. Diabetic foot infections: stepwise medical and surgical management. Int Wound J. 2004 Jun;1(2):123–32.

  13. Dalla PL, Faglia E. Treatment of diabetic foot ulcer: an overview strategies for clinical approach. Curr Diabetes Rev. 2006 Nov;2(4):431–47.

  14. Ha Van G. [Management of a diabetic foot ulcer]. Rev Med Interne. 2008 Sep;29 Suppl 2:S238–S42.

  15. Smiell JM, Wieman TJ, Steed DL, Perry BH, Sampson AR, Schwab BH. Efficacy and safety of becaplermin (recombinant human plateletderived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies. Wound Repair Regen. 1999 Sep– Oct;7(5):335–46.

  16. Gregor S, Maegele M, Sauerland S, Krahn JF, Peinemann F, Lange S. Negative pressure wound therapy: a vacuum of evidence? Arch Surg. 2008 Feb;143(2):189–96.

  17. Berlanga-Acosta J, Gavilondo J, García del Barco D, Martín J, Guillén G. Epidermal Growth Factor (EGF) and Platelet-Derived Growth Factor (PDGF) as tissue healing agents: Clarifying concerns about their possible role in malignant transformation and tumor progression. J Carcinogene Mutagene. 2011 Feb 25;2(1):100–15.

  18. Cohen IK, Crossland MC, Garrett A, Diegelmann RF. Topical application of epidermal growth factor onto partial-thickness wounds in human volunteers does not enhance reepithelialization. Plast Reconstr Surg. 1995 Aug;96(2):251–4.

  19. Schultz GS, Sibbald RG, Falanga V, Ayello EA, Dowsett C, Harding K, et al. Wound bed preparation: a systematic approach to wound management. Wound Repair Regen. 2003 Mar;11 Suppl 1:S1–28.

  20. Sibbald RG, Orsted H, Schultz GS, Coutts P, Keast D; International Wound Bed Preparation Advisory Board. Preparing the wound bed 2003: focus on infection and inflammation. Ostomy Wound Manage. 2003 Nov;49(11):23–51.

  21. Berlanga J, Lodos J, Reyes O, Caballero E, Lopez Saura P. Epidermal growth factor stimulated re-epithelialization in pigs. The possible role of acute wound proteases. Biotecnol Aplicada. 1998;15(2):83–7.

  22. Saarialho-Kere UK. Patterns of matrix metalloproteinase and TIMP expression in chronic ulcers. Arch Dermatol Res. 1998 Jul;290 Suppl:S47–54.

  23. Mast BA, Schultz GS. Interactions of cytokines, growth factors, and proteases in acute and chronic wounds. Wound Repair Regen. 1996 Oct;4(4):411–20.

  24. Buckley A, Davidson JM, Kamerath CD, Wolt TB, Woodward SC. Sustained release of epidermal growth factor accelerates wound repair. Proc Natl Acad Sci USA. 1985 Nov;82(21):7340–4.

  25. Prats PA, Duconge J, Valenzuela C, Berlanga J, Edrosa CR, Fernández-Sánchez E. Disposition and receptor-site binding of (125)I-EGF after topical administration to skin wounds. Biopharm Drug Dispos. 2002 Mar;23(2):67–76.

  26. Falanga V, Eaglstein WH, Bucalo B, Katz MH, Harris B, Carson P. Topical use of human recombinant epidermal growth factor (h-EGF) in venous ulcers. J Dermatol Surg Oncol. 1992 Jul;18(7):604–6.

  27. Falanga V. Growth factors and chronic wounds: the need to understand the microenvironment. J Dermatol. 1992 Nov;19(11):667–72.

  28. Berlanga-Acosta J, Gavilondo-Cowley J, López- Saura P, González-López T, Castro-Santana MD, López-Mola E, et al. Epidermal growth factor in clinical practice - a review of its biological actions, clinical indications and safety implications. Int Wound J. 2009 Oct;6(5):331–46.

  29. Berlanga J, Caballero E, Prats P, López Saura P, Playford RJ. [The role of the epidermal growth factor in cell and tissue protection]. Med Clin (Barc). 1999 Sep 4;113(6):222–9.

  30. Berlanga-Acosta J, Playford RJ, Mandir N, Goodlad RA. Gastrointestinal cell proliferation and crypt fission are separate but complementary means of increasing tissue mass following infusion of epidermal growth factor in rats. Gut. 2001 Jun;48(6):803–7.

  31. Mishra S, Murphy LC, Nyomba BL, Murphy LJ. Prohibitin: a potential target for new therapeutics. Trends Mol Med. 2005 Apr;11(4):192–7.

  32. Hollier B, Harkin DG, Leavesley D, Upton Z. Responses of keratinocytes to substrate-bound vitronectin: growth factor complexes. Exp Cell Res. 2005 Apr 15;305(1):221–32.

  33. Stanley AC, Park HY, Phillips TJ, Russakovsky V, Menzoian JO. Reduced growth of dermal fibroblasts from chronic venous ulcers can be stimulated with growth factors. J Vasc Surg. 1997 Dec;26(6):994–9.

  34. Loots MA, Lamme EN, Mekkes JR, Bos JD, Middelkoop E. Cultured fibroblasts from chronic diabetic wounds on the lower extremity (noninsulin- dependent diabetes mellitus) show disturbed proliferation. Arch Dermatol Res. 1999 Feb–Mar;291(2–3):93–9.

  35. Berlanga J, Fernández JI, Valdés C, Franco N, Rojas I, Santana H, et al, inventors; Centro de Ingeniería Genética Biotechnología, assignee. Use of a pharmaceutical composition containing epidermal growth factor (EGF) for diabetic foot amputation prevention. World patent WO PCT/ CU2002/000011. 2008 Dec 18.

  36. Berlanga-Acosta J. Diabetic lower extremity wounds: the rationale for growth factors-based infiltration treatment. Int Wound J. 2011 Dec;8(6):612–20.

  37. Acosta JB, Savigne W, Valdez C, Franco N, Alba JS, del Río A, et al. Epidermal growth factor intralesional infiltrations can prevent amputation in patients with advanced diabetic foot wounds. Int Wound J. 2006 Sep;3(3):232–9.

  38. Fernández-Montequín JI, Infante-Cristiá E, Valenzuela- Silva C, Franco-Pérez N, Savigne-Gutierrez W, Artaza-Sanz H, et al. Intralesional injections of Citoprot P® (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation. Int Wound J. 2007 Dec;4(4):333–43.

  39. Fernández-Montequín JI, Betancourt BY, Leyva- Gonzalez G, López Mola E, Galán-Naranjo K, Ramírez-Navas M, et al. Intralesional administration of epidermal growth factor-based formulation (Heberprot-P) in advanced diabetic foot ulcer: Treatment up to complete wound closure. Int Wound J. 2009 Feb;6(1):67–72.

  40. Fernández-Montequín JI, Valenzuela-Silva CM, González-Díaz O, Savigne W, Sancho-Soutelo N, Rivero-Fernández F, et al. Intra-lesional injections of recombinant human Epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers. Multicenter, randomized, placebo-controlled, double blind study. Int Wound J. 2009 Dec;6(6):432–43.

  41. Hernández Rivero MJ, Llanes Barrios JA, Acosta Lapera DS. [Heberprot-P, an effective therapy for prevention of diabetic foot amputation]. Rev Cubana Angiol Cirugía Vascular. 2009;10(1):3–11.

  42. Valenzuela-Silva CM, Tuero-Iglesias AD, García- Iglesias E, González-Díaz O, del Río-Martín A, Yera-Alos IB, et al. Granulation Response and Partial Wound Closure predict Healing in Clinical Trials on Advanced Diabetes Foot Ulcers Treated with Recombinant, Human Epidermal Growth Factor. Diabetes Care. 2012 Sep 10. [Epub ahead of print]

  43. Ló pez-Saura PA, Berlanga-Acosta J, Ferná ndez- Montequí n JI, Valenzuela-Silva C, Gonzá lez- Dí az O, Savigne W, et al. Intralesional Human Recombinant Epidermal Growth Factor for the Treatment of Advanced Diabetic Foot Ulcer: From Proof of Concept to Confirmation of the Efficacy and Safety of the Procedure. In: Dinh T, editor. Global Perspective on Diabetic Foot Ulcerations. Rijeka (HR): InTech; 2011 Dec 9. 278 p.

  44. Blume P, Driver VR, Tallis AJ, Kirsner RS, Kroeker R, Payne WG, et al. Formulated collagen gel accelerates healing rate immediately after application in patients with diabetic neuropathic foot ulcers. Wound Repair Regen. 2011 May–Jun;19(3):302–8.

  45. Taylor SM, Johnson BL, Samies NL, Rawlinson RD, Williamson LE, Davis SA, et al. Contemporary management of diabetic neuropathic foot ulceration: a study of 917 consecutively treated limbs. J Am Coll Surg. 2011 Apr;212(4):532–45.

  46. CDC [Internet]. Atlanta (US): Center for Disease Control and Prevention (US); 2012. 2011 National Diabetes Fact Sheet; [updated 2012 Jan; cited 2012 Sep]; [2.7 MB]. Disponible en: www.cdc .gov/diabetes/pubs/pdf/ndfs_2011.pdf

  47. Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA. 2005 Jan 12;293(2):217–28.

  48. International Diabetes Federation. IDF Diabetes Atlas, 4th ed. Brussels (BE): International Diabetes Federation; 2007.

  49. Yost ML. Diabetic Foot Ulcers, peripheral artery disease and critical limb ischemia, 2010. Atlanta, Georgia: The SAGE Group; 2010.




2020     |     www.medigraphic.com